Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Striatal D2 dopaminergic receptors assessed with positron emission tomography and [76Br]bromospiperone in untreated schizophrenic patients.

Martinot JL, Peron-Magnan P, Huret JD, Mazoyer B, Baron JC, Boulenger JP, Loc'h C, Maziere B, Caillard V, Loo H, et al.

Am J Psychiatry. 1990 Jan;147(1):44-50.

PMID:
2293788
2.

The estimated density of D2 striatal receptors in schizophrenia. A study with positron emission tomography and 76Br-bromolisuride.

Martinot JL, Paillère-Martinot ML, Loc'h C, Hardy P, Poirier MF, Mazoyer B, Beaufils B, Mazière B, Allilaire JF, Syrota A.

Br J Psychiatry. 1991 Mar;158:346-50.

PMID:
1827999
3.

Striatal D2 dopaminergic receptor status ascertained in vivo by positron emission tomography and 76Br-bromospiperone in untreated schizophrenics.

Martinot JL, Huret JD, Peron-Magnan P, Mazoyer BM, Baron JC, Caillard V, Syrota A, Loo H.

Psychiatry Res. 1989 Sep;29(3):357-8. No abstract available.

PMID:
2575262
4.

Striatal D2 dopamine receptor characteristics in neuroleptic-naive schizophrenic patients studied with positron emission tomography.

Hietala J, Syvälahti E, Vuorio K, Någren K, Lehikoinen P, Ruotsalainen U, Räkköläinen V, Lehtinen V, Wegelius U.

Arch Gen Psychiatry. 1994 Feb;51(2):116-23.

PMID:
7905257
5.

In vivo quantitative imaging of dopamine receptors in human brain using positron emission tomography and [76Br]bromospiperone.

Mazière B, Loc'h C, Baron JC, Sgouropoulos P, Duquesnoy N, D'Antona R, Cambon H.

Eur J Pharmacol. 1985 Aug 27;114(3):267-72.

PMID:
3877639
6.

Uptake of 77Br-spiperone in the striata of schizophrenic patients and controls.

Crawley JC, Crow TJ, Johnstone EC, Oldland SR, Owen F, Owens DG, Smith T, Veall N, Zanelli GD.

Nucl Med Commun. 1986 Aug;7(8):599-607. Erratum in: Nucl Med Commun 1987 Feb;8(2):121.

PMID:
2946010
7.

Loss of striatal [76Br]bromospiperone binding sites demonstrated by positron tomography in progressive supranuclear palsy.

Baron JC, Mazière B, Loc'h C, Cambon H, Sgouropoulos P, Bonnet AM, Agid Y.

J Cereb Blood Flow Metab. 1986 Apr;6(2):131-6.

PMID:
3485639
8.

Striatal dopamine D2 receptors in tardive dyskinesia: PET study.

Blin J, Baron JC, Cambon H, Bonnet AM, Dubois B, Loc'h C, Mazière B, Agid Y.

J Neurol Neurosurg Psychiatry. 1989 Nov;52(11):1248-52.

9.

Elevation of dopamine D2 receptors in schizophrenia is underestimated by radioactive raclopride.

Seeman P, Niznik HB, Guan HC.

Arch Gen Psychiatry. 1990 Dec;47(12):1170-2. No abstract available.

PMID:
2244801
10.

77Br-p-bromospiperone: a ligand for in vivo labelling of dopamine receptors.

Owen F, Poulter M, Mashal RD, Crow TJ, Veall N, Zanelli GD.

Life Sci. 1983 Aug 22;33(8):765-8.

PMID:
6888192
11.

In vivo D2 dopamine receptor density in psychotic and nonpsychotic patients with bipolar disorder.

Pearlson GD, Wong DF, Tune LE, Ross CA, Chase GA, Links JM, Dannals RF, Wilson AA, Ravert HT, Wagner HN Jr, et al.

Arch Gen Psychiatry. 1995 Jun;52(6):471-7.

PMID:
7771917
12.

Dopamine-Related Disruption of Functional Topography of Striatal Connections in Unmedicated Patients With Schizophrenia.

Horga G, Cassidy CM, Xu X, Moore H, Slifstein M, Van Snellenberg JX, Abi-Dargham A.

JAMA Psychiatry. 2016 Aug 1;73(8):862-70. doi: 10.1001/jamapsychiatry.2016.0178.

PMID:
27145361
13.

Striatal D(2) dopamine receptor density and psychotic symptoms in schizophrenia: a longitudinal study.

Syvälahti EK, Räkköläinen V, Aaltonen J, Lehtinen V, Hietala J.

Schizophr Res. 2000 Jun 16;43(2-3):159-61. No abstract available.

PMID:
10858634
14.

Central D2 receptors and negative symptoms of schizophrenia.

Martinot JL, Paillère-Martinot ML, Loc'h C, Lecrubier Y, Dao-Castellana MH, Aubin F, Allilaire JF, Mazoyer B, Mazière B, Syrota A.

Br J Psychiatry. 1994 Jan;164(1):27-34.

PMID:
8137107
15.

Dopamine D2 receptor density estimates in schizophrenia: a positron emission tomography study with 11C-N-methylspiperone.

Tune LE, Wong DF, Pearlson G, Strauss M, Young T, Shaya EK, Dannals RF, Wilson AA, Ravert HT, Sapp J, et al.

Psychiatry Res. 1993 Dec;49(3):219-37.

PMID:
7909948
16.

Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort.

Abi-Dargham A, Gil R, Krystal J, Baldwin RM, Seibyl JP, Bowers M, van Dyck CH, Charney DS, Innis RB, Laruelle M.

Am J Psychiatry. 1998 Jun;155(6):761-7.

PMID:
9619147
17.

76Br-bromospiroperidol: a new tool for quantitative in-vivo imaging of neuroleptic receptors.

Mazière B, Loc'h C, Hantraye P, Guillon R, Duquesnoy N, Soussaline F, Naquet R, Comar D, Mazière M.

Life Sci. 1984 Sep 24;35(13):1349-56.

PMID:
6332966
18.

High central D2-dopamine receptor occupancy as assessed with positron emission tomography in medicated but therapy-resistant schizophrenic patients.

Coppens HJ, Slooff CJ, Paans AM, Wiegman T, Vaalburg W, Korf J.

Biol Psychiatry. 1991 Apr 1;29(7):629-34.

PMID:
1675892
19.

Correlation between fine motor activity and striatal dopamine D2 receptor density in patients with schizophrenia and healthy controls.

Yang YK, Chiu NT, Chen CC, Chen M, Yeh TL, Lee IH.

Psychiatry Res. 2003 Jul 30;123(3):191-7.

PMID:
12928107
20.

Serial [18F]N-methylspiroperidol PET studies to measure changes in antipsychotic drug D-2 receptor occupancy in schizophrenic patients.

Smith M, Wolf AP, Brodie JD, Arnett CD, Barouche F, Shiue CY, Fowler JS, Russell JA, MacGregor RR, Wolkin A, et al.

Biol Psychiatry. 1988 Apr 1;23(7):653-63.

PMID:
2967093

Supplemental Content

Support Center